Clinical Trial

Tolerability and Efficacy of CBD Extract for RLS Treatment

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study plans to learn more about the safety and tolerability of high Cannabidiol (CBD) cannabis extract (BRC-002) for use in Idiopathic Restless Legs Syndrome. Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-03.
Trial Details
NCT Number NCT07224932
Lead Sponsor University of Colorado, Denver
Collaborators: Biopharmaceutical Research Company
Conditions Restless Leg Syndrome
Enrollment 60 participants
Start Date 2025-12-19
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-02-25 (estimated)
Updated on ClinicalTrials.gov 2025-11-13